Abstract
Preclinical and clinical observations suggest that enhancement of prostaglandin activity inhibits catecholamine release and may have antidyskinetic effects. A double-blind therapeutic trial with prostaglandin precursor essential fatty acids was conducted in 16 patients with tardive dyskinesia. No beneficial effects were seen.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Clinical Trials as Topic
-
Double-Blind Method
-
Dyskinesia, Drug-Induced / drug therapy*
-
Dyskinesia, Drug-Induced / metabolism
-
Humans
-
Linolenic Acids / administration & dosage
-
Linolenic Acids / metabolism
-
Linolenic Acids / therapeutic use*
-
Male
-
Middle Aged
-
Prostaglandins E / metabolism
-
gamma-Linolenic Acid
Substances
-
Linolenic Acids
-
Prostaglandins E
-
gamma-Linolenic Acid